{"title":"伏诺哌赞成功治疗难治性胃食管反流性慢性咳嗽3例报告","authors":"Tong-Yang-Zi Zhang, Lu-Di Fei, Ji-Guang Wu, Yi-Qing Zhu, Wan-Zhen Li, Sheng-Yuan Wang, Xiang-Huai Xu, Li Yu","doi":"10.1016/j.amjms.2025.08.019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.</p><p><strong>Methods: </strong>This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.</p><p><strong>Results: </strong>All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.</p><p><strong>Conclusions: </strong>Vonoprazan is a promising clinical application in the treatment of refractory GERC.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases.\",\"authors\":\"Tong-Yang-Zi Zhang, Lu-Di Fei, Ji-Guang Wu, Yi-Qing Zhu, Wan-Zhen Li, Sheng-Yuan Wang, Xiang-Huai Xu, Li Yu\",\"doi\":\"10.1016/j.amjms.2025.08.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.</p><p><strong>Methods: </strong>This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.</p><p><strong>Results: </strong>All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.</p><p><strong>Conclusions: </strong>Vonoprazan is a promising clinical application in the treatment of refractory GERC.</p>\",\"PeriodicalId\":94223,\"journal\":{\"name\":\"The American journal of the medical sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American journal of the medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjms.2025.08.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2025.08.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Successful treatment of refractory gastroesophageal reflux-induced chronic cough with vonoprazan: a report of three cases.
Background: Gastroesophageal reflux-induced chronic cough (GERC) is a common cause of chronic cough, with an increasing incidence over the years. Proton-pump inhibitors (PPIs) are the standard treatment for GERC, but some patients exhibit poor response to PPIs. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers enhanced acid inhibition compared to PPIs and has shown effectiveness in treating GERC. However, its efficacy in refractory GERC cases has not been widely reported.
Methods: This report examines three cases of refractory GERC in which patients did not experience significant symptom relief after 8 weeks of PPI treatment. The treatment was switched to vonoprazan to evaluate its effectiveness in alleviating chronic cough symptoms.
Results: All three patients demonstrated complete relief from chronic cough after the transition to vonoprazan, indicating its potential effectiveness in cases where PPIs failed to provide sufficient symptom control.
Conclusions: Vonoprazan is a promising clinical application in the treatment of refractory GERC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
